Influence of Bifidobacterium probiotic therapy on ovariectomized rats and experimental periodontitis. immunohistochemical analysis

• Grant number: 19/21514-9
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: June 01, 2020
• End date: August 31, 2021
• Field of knowledge: Health Sciences - Dentistry - Periodontology
• Principal Investigator: Michel Reis Messora
• Grantee: Mariana Dias Corpa Tardelli
• Host Institution: Faculdade de Odontologia de Ribeirão Preto (FORP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

Increased production of proinflammatory cytokines is an important factor in the pathogenesis and progression of periodontal disease and osteoporosis. Modulation of expression of bone tissue markers and intestinal permeability by probiotics may be a potential alternative treatment when both conditions are associated. The purpose of this study will be to evaluate the effect of probiotic agent Bifidobacterium animalis subs. Lactis (B. lactis) HN019 on inflammatory profile of periodontal tissues in ovariectomized rats with ligature-induced periodontitis. 32 rats divided into 4 groups will be used: C-OVX (control without probiotic), C-OVX-HN019 (control with probiotic), DP-OVX (periodontal disease) and DP-OVX-HN019 (periodontal disease with probiotic). On day 0 of the experiment, all animals will undergo ovariectomy. After 8 weeks, animals from groups HN019 will receive systemic administration of the probiotic strain B. lactis (1.5 x 108 Colony Forming Units / mL) for 8 weeks. 14 weeks after the start of the experiment, animals from Groups DP-OVX and DP-OVX-HN019 will be placed in bandages around the lower first molars to induce periodontal disease, and these animals will also receive topical probiotic therapy administrations on placement of the ligatures as well as at 3 and 7 days after the placement of the ligatures. All animals will be euthanized 16 weeks after the start of the experiment. The hemi-mandible will be collected for determination. of markers of bone metabolism (tartrate resistant acid phosphatase - TRAP, osteoprotegerin - OPG and nuclear factor activator receptor ligand kappa B - RANKL) by immunohistochemistry. The small intestine will be collected for determination of intestinal permeability markers (e-cadherin and claudine) by immunohistochemistry. The data obtained will be submitted to statistical analysis (P <0.05).